February 3, 2015
by Lysimachos Zografos
Comments Off on Parkure’s CEO awarded fellowship from Royal Society of Edinburgh

Parkure’s CEO awarded fellowship from Royal Society of Edinburgh

rse_enterprise_fellowships_logo_small

The Royal Society of Edinburgh (RSE) is Scotland’s national academy of science and letters. As part of their invaluable support to Scottish Life Sciences they offer Enterprise Fellowships in order to enable promising science and technology researchers to grow into successful entrepreneurs.

We are delighted to announce that Parkure’s CEO, Dr. Lysimachos Zografos was awarded the RSE  Enterprise Fellowship in order to pursuit the successful development of the company. The fellowship offers financial support as well as training, mentoring and access to networks of influential individuals.

February 3, 2015
by Lysimachos Zografos
Comments Off on Parkure at EIE15

Parkure at EIE15

Screen Shot 2015-02-02 at 18.33.45

We are delighted to announce that Parkure will be at this year’s instalment of Engage Invest Exploit (EIE15), Scotland’s premier technology investor showcase. EIE15 is organised by University of Edinburgh Informatics Ventures and offers the opportunity to a few selected companies to pitch to panels of investors.

After launching there last year, Parkure was invited again this time to show the progress made and interact with investors in order to raise funding for a full-scale screen of more than 40,000 compounds. Maximising the number of compounds we test will maximise the probability of finding drugs that can stop the progression of Parkinson’s, potentially leading to a cure.

February 3, 2015
by Lysimachos Zografos
Comments Off on Parkinson’s UK visit to Parkure

Parkinson’s UK visit to Parkure

Untitled-1

On 7th January 2015 a group of six members of the Edinburgh Research Interest Group of Parkinson’s UK visited Parkure. We had the chance to introduce ourselves and explain our research in a bit more detail. Informal visits like this give us the opportunity to interact more with those directly affected by Parkinson’s so we can focus more on what matters. You can read what the Edinburgh Research Interest Group of Parkinson’s UK said about their visit here.

January 19, 2015
by Lysimachos Zografos
Comments Off on Living with young onset Parkinson’s

Living with young onset Parkinson’s

Screen Shot 2015-01-19 at 17.41.47

Thinking of Parkinson’s disease as something that could only affect your gran is a common misconception. Sadly it is a little known fact that 1 in 20 people diagnosed with Parkinson’s disease are under the age of 40. Young onset Parkinson’s disease (YOPD) is the diagnosis with Parkinson’s before the age of 50. YOPD has also been associated with – but not limited to – mutations of a specific gene, LRRK2.

Continue Reading →

January 6, 2015
by Lysimachos Zografos
Comments Off on The personal burden of Parkinson’s disease

The personal burden of Parkinson’s disease

Hands

Having discussed the financial cost of Parkinson’s disease, it is time to discuss the most important aspect, the personal burden. Parkinson’s affects 1 in 100 people over the age of 60. Although this entry focuses on the effects of Parkinson’s on the  lives of the older among us, we have to also remember that 1 in 5 diagnosed are between 18 and 64…

Continue Reading →

December 17, 2014
by Lysimachos Zografos
Comments Off on The Cost of Parkinson’s disease

The Cost of Parkinson’s disease

money+troubles

The real price of any disease is all that it causes to the sufferers and carers. But have you ever thought how this affects you? Parkinson’s as any other disease poses an economic burden both to sufferers and to national health systems, where these are available. But how much does it really cost?

Continue Reading →

November 13, 2014
by Lysimachos Zografos
Comments Off on News: Parkure awarded SMART grant from Scottish Enterprise

News: Parkure awarded SMART grant from Scottish Enterprise

We are very happy to announce that we have been awarded with a Scottish Enterprise SMART:Scotland grant to do further R&D on the search for drugs that stop the progression of Parkinson’s disease. The grant is dependent on us raising enough seed funding from our equity crowdfunding campaign.  You can support us by pledging and investing in our equity crowdfunding campaign.

logo